Edition:
United Kingdom

Clearside Biomedical Inc (CLSD.OQ)

CLSD.OQ on NASDAQ Stock Exchange Global Market

6.75USD
8:27pm GMT
Change (% chg)

$-0.30 (-4.26%)
Prev Close
$7.05
Open
$7.06
Day's High
$7.09
Day's Low
$6.64
Volume
27,465
Avg. Vol
43,060
52-wk High
$10.46
52-wk Low
$5.44

Latest Key Developments (Source: Significant Developments)

Clearside Biomedical Q3 loss per share $0.72
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Clearside Biomedical Inc ::Clearside Biomedical, Inc. Announces third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.72.Q3 earnings per share view $-0.55 -- Thomson Reuters I/B/E/S.  Full Article

Clearside Biomedical announces completion of patient enrollment in phase 2 clinical trial of CLS-TA
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Clearside Biomedical Inc :Clearside Biomedical announces completion of patient enrollment in phase 2 clinical trial of CLS-TA used together with Eylea in patients with diabetic macular edema.Clearside Biomedical Inc - ‍patient follow-up in Tybee trial is 6 months​.  Full Article

Clearside Biomedical says entered amended and restated loan and security agreement
Tuesday, 4 Oct 2016 

Clearside Biomedical Inc : On september 28, 2016, entered into an amended and restated loan and security agreement . Of $8 million term loan drawn on sept 28, about $5.3 million used to repay existing principal, interest obligations under original loan agreement. .Amended, restated loan agreement provides up to $15.0 million in new term loans of which $8 million was funded on sept 28-sec filing.  Full Article

Clearside Biomedical Q2 loss per share $0.62
Thursday, 11 Aug 2016 

Clearside Biomedical Inc : Q2 loss per share $0.62 . Clearside biomedical, inc. Reports second quarter 2016 financial results .Q2 earnings per share view $-0.39 -- Thomson Reuters I/B/E/S.  Full Article

Clearside Biomedical provides update on phase 2 TANZANITE trial
Tuesday, 26 Jul 2016 

Clearside Biomedical Inc : 78 percent of patients required no additional treatment in trial arm with Concomitant Suprachoroidally Administered Zuprata™ and Intravitreally Administered Eylea . Patients reached an average BCVA improvement of 19 letters over a 3-month period . Expects to have an end-of-phase 2 meeting with U.S. Food and Drug Administration (FDA) in second half of 2016 .Upon FDA feedback,intends to commence phase 3 clinical program for treatment of macular edema associated with RVO in H1 of 2017.  Full Article

Wellington Management Group LLP reports 10.65 pct passicve stake in Clearside Biomedical
Monday, 11 Jul 2016 

: Wellington Management Group LLP reports 10.65 pct passicve stake in Clearside Biomedical as of June 30, 2016 - SEC Filing Source - http://bit.ly/29t07xm Further company coverage: [CLSD.O] (Bengaluru Newsroom; +1 646 223 8780).  Full Article

Clearside Biomedical shares open at $8.00 in debut
Thursday, 2 Jun 2016 

: Clearside Biomedical Inc shares open at $8.00 in debut, above the IPO price of $7 Further company coverage: [CLSD.O] ((Bengaluru Newsroom +1 646 223 8780;)).  Full Article

Clearside Biomedical prices initial public offering at $7.00 per share
Thursday, 2 Jun 2016 

Clearside Biomedical Inc : Says initial public offering of 7.20 million common shares priced at $7.00 per share .Clearside biomedical, inc. Announces pricing of initial public offering.  Full Article

Clearside Biomedical sees IPO of 7.2 mln shares priced at $7 each
Wednesday, 1 Jun 2016 

Clearside Biomedical Inc : Clearside Biomedical Inc sees IPO of 7.2 million shares of its common stock - sec filing . Clearside biomedical inc sees IPO priced at $7 per share .Clearside Biomedical Inc had Previously Expected Ipo Of 4 Mln Shares Of Its Common Stock To Be Priced Between $14 and $16 each.  Full Article

BRIEF-Clearside Biomedical Q3 loss per share $0.72

* Clearside Biomedical, Inc. Announces third quarter 2017 financial results and provides corporate update